Zicam Maker Takes Cues From J&J

Posted by: Arlene Weintraub on June 24, 2009

A product recall is every company’s worst nightmare. But for tiny Matrixx Initiatives (MTXX)—maker of Zicam cold remedies—the June 16 recall of two of its products was particularly painful. The company’s herbal nasal gel and swabs, recalled because of reports that some patients lost their sense of smell after using them, accounted for 40% of Matrixx’s $112 million in sales last year. Matrixx’s stock dropped a sickening 70% to $5.78 on the day of the recall.

Luckily, Matrixx’s acting president William Hemelt had a lot of advice from three board members who know a thing or two about responding to a product crisis. Chairman William Egan, and directors Lori Bush and Michael Zeher are all veterans of Johnson & Johnson, the company that is still held up as the model of good corporate citizenship for its handling of the 1982 Tylenol scare. “We talked about Tylenol many times,” Hemelt said in a phone conversation a week after the Zicam recall. Hemelt’s most important takeaway: “Being up front with people is a good idea.”

Matrixx executives have spent the last week doing some big-time damage control. They had a shareholder meeting on the 18th, and have been busy updating the Zicam Web site to keep customers fully informed. Click on that site today and you’ll see a video of Hemelt himself urging customers to return any gel or swab they may have for a complete refund. “Your safety has always been and will continue to be our number one priority at Zicam,” Hemelt says in the video. He adds that the company has requested a meeting with FDA officials to “show them our extensive safety data.”

What’s particularly challenging for Matrixx, however, is that Zicam is one of only three brands it owns, so its entire corporate identity is tied up in it. And even though there are still 17 Zicam products on store shelves, the overall brand image has taken a serious hit. Hemelt hopes that communicating openly with customers will be the key to restoring the brand’s cache. On June 22, the company took out a full page ad in the New York Times that blared “Thanks to our millions of loyal Zicam users! We’re still here for you!” It pointed readers to the Web site, where they could also download a coupon.

And Matrixx has been out front about its legal liability, with a Web site it dubbed zicamlawsuits.com. It sounds like a site that a voracious product-liability lawyer might invent to recruit patients who want to file claims. But in fact, Matrixx put the site up as a repository for documents from the 10 federal lawsuits that have been filed against the company. “We’ve been very successful in this litigation,” Hemelt says. “We’re trying to correct misinformation.”

Will the massive PR push be enough to save the brand? Even Hemelt can’t say for sure. He hopes the lull before cold-and-flu season will give him some time to save face with customers, before they start looking for relief from their sniffles. “We will take whatever steps we can afford to protect the brand,” he says. Unfortunately, though, he’s lacking one of the biggest assets that saved J&J after the Tylenol crisis: lots of other strong brands to soften the blow.

Reader Comments

edwards

June 24, 2009 2:43 PM

This company has no future. Any day now it is going to be the target of a massive, company-destroying class action suit. Expect lawyers to pile on, both on behalf of injured consumers and irate investors. The domain (web address) MatrixxClassAction.com has already been registered and is for sale. It's likely to be just one of many vehicles lawyers will use to educate consumers and investors, and attract plaintiffs.

katherine

June 24, 2009 3:08 PM

Matrixx Initiatives has successfully been down this road before and knows how to hold their own against plotting lawyers. The bottom-line is that there's no support or proof that Zicam causes anosmia. What can be proven is that the common cold causes anosmia.

Joshua

June 25, 2009 3:10 AM

Matrixx has drawn the attention of the SEC: http://www.newsinferno.com/archives/7199

J. Long

June 25, 2009 1:37 PM

I am looking at how much MTXX could really be at risk to lose, should the law suits expand into a much larger class action suit. In the call last week, the CEO mentioned that they do hold liability insurance, but at this point the deductible has not been reached. It was also mentioned that the typical lawsuit runs about $500k to contest. However, one cannot just multiply $500k times the potential number of known litigants, as now things are turning into a class action case. The class action route may actually be a good thing for share holders, as presumably that would be a single liability action and would fall under a single action in terms the insurance deductible. So, once the deductible has been met, the shareholder liability peaks. So, does anyone know what that amount is?

The larger issue is the brand damage, but in my view, that is no longer an issue. It appears that the long view for the products is no longer the brand. The brand is permanently damaged and may need to be re-branded. However, nothing will happen unless the FDA releases the products. If this happens, the company will either start a new brand or spin-off the product line; the former being more likely and more lucrative for the shareholders in the long-term.

Additional possible upside is that a replacement product line is being introduce, with similar margins, and an oral delivery system, getting away from the nasal problem. It should not be a surprise when the next earnings call happens, that the revenue forecast for rest of the year will not be a 50% dip (the lost revenue from the products pulled). It is likely that the dip will only be 25% or less, as retailers and customers are asking for a replacement for the products pulled.

So, short of panic dips caused by news designed to build fodder for the class action suit or the shorts (which by the way should already be baked into the price, we all know the suit is coming, which is why the stock price was at an 11 year low two days ago), the stock should see a long-term recovery once things settle. The biggest question is will the company be able to show that the products are safe.

Floyd

June 25, 2009 4:37 PM

Co-Inventor of Zicam a 2 time FDA warning letter loser. Hensley encoraged the public to "stockpile" the bogus bird flu cure.
---------------------------------------------------------
VIRA 38 Production Capacity Increased to Meet the Needs of Bird Flu Afflicted Nations
PRB Pharmaceuticals and Lee's Pharmaceuticals announced today that they have stepped up production capacity of VIRA 38. "As we move closer to the emergence of an influenza pandemic, we find personal stockpiling of VIRA 38 becoming more widespread," said Dr. Charles Hensley, Chairman and CEO of PRB Pharmaceuticals. "In life or death situations, people tend to take matters into their own hands rather than relying on government institutions."
============================================
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Department of Health and Human Services Public Health Service
Food and Drug Administration
Los Angeles District
19701 Fairchild
Irvine, California 92612-25062
Telephone : (949) 608-2900
Warning Letter
VIA FEDERAL EXPRESS
RETURN RECEIPT REQUESTED
November 23, 2005
W/L 08-06
Charles B. Hensley, Ph.D.
PRB Pharmaceuticals
300 Oceangate
Suite 910
Long Beach, CA 90802
Dear Dr. Hensley:
This letter concerns your firm’s marketing of the product “Vira 38″ on your website, www,prbpharmaceuticals.com. According to your website, this product is intended to prevent, treat, or cure serious disease conditions. The statements on your website include, but are not limited to, the following:
Vira 38
“Highly effective flu medication.”
Shown to inhibit and prevent infection of Bird Flu Virus (H5N1) and Type A human influenza in vitro.”
“Human clinical research shows Vira 38 reduces the duration of influenza illness by 78%.”
“One of the anti-viral components is v38 AMF-1 which has been shown to inhabit infections from Type A influenza, SARS virus, Avian influenza virus, Staphylococcus aureus, and Streptococcus pneumoniae (two bacteria primarily responsible for secondary infections seen in influenza).”
“Vira 38 is a favorite among the Hong Kong doctors for the prevention and treatment of influenza.”
“vira 38 is currently used in Hong Kong to protect the live poultry market workers against the bird flu.”
“Vira 38 was used by the major SARS hospital to protect front-line doctors and nurses against SARS during the SARS outbreak of 2003.”
These claims are further supplemented by the metatags that you use to bring consumers to your website. These metatags include “life threatening diseases,” “influenza virus,” “SARS coronavirus.” and treatments” .
Vira 38 is a drug, as defined by Section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (Act), 21 U.S.C. 321 (g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. Moreover, this product is a new drug, as defined by Section 201(p) of the Act, 21 U.S.C. 321(P), because it is not generally recognized as safe and effective for its labeled uses. Under Sections 301(d) and 505(a) of the Act, 21 U.S.C. 331 (d) and 355(a), a new drug may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved application is in effect for it. Your sale of Vira 38 without such an approved application violates these provisions of the Act.
Furthermore, many of the conditions for which this product is offered are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use for these conditions cannot be written so that a layman can use thus drug safely for its intended purposes. (See 21 C.F.R § 201.5). Because your product’s labeling fails to bear adequate directions for its intended uses, it is misbranded under Section 502(f)(1) of the Act, 21 U.S.C., § 352(f)(1).
The above violations are not intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure that the drug products that you manufacture or distribute meet all of the requirements of the Act and its implementing regulations. Federal agencies are advised of the issuance of all warning letter about drugs and devices so that they may take this information into account when considering the award of contracts.
You must immediately correct these violations. It you do not immediately correct them, you may be subject to enforcement action against you without further notice. The Act provides for seizure of illegal products and for an injunction against the manufacturers and distributors of illegal products.
You must notify this office in writing within 15 working days of receipt of this letter as to the steps that you have taken to correct the above-listed violations and the steps taken to assure that similar violations will not occur. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be made. Additionally, if your firm does not manufacture the product identified above, your reply should include the name and address of the manufacturer. If the firm from which you receive the product is not the manufacturer, please include the name of your supplier in addition to the manufacturing firm. Address your reply to the U.S. Food and Drug Administration, 19701 Fairchild, Irvine, CA 92612, Attention: Pamela B. Schweikert, Director of Compliance.
A description of the new drug approval process can be found on FDA’s Internet Website at http://www.fda.gov/cder/regulatory/app lications/default.htm. Any questions you may have regarding this process should be directed to the Food and Drug Administration, Division of Drug Information (HFD-240), Center for Drug Evaluation and Research, 5600 Fishers Lane, Rockville, Maryland 20857.
Sincerely,
/s/
Alonza E. Cruse
Director, Los Angeles District
FOI Home Page | Most Recent Warning Letters
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility

VIRA 38 Production Capacity Increased to Meet the Needs of Bird Flu Afflicted Nations
PRB Pharmaceuticals and Lee's Pharmaceuticals announced today that they have stepped up production capacity of VIRA 38. "As we move closer to the emergence of an influenza pandemic, we find personal stockpiling of VIRA 38 becoming more widespread," said Dr. Charles Hensley, Chairman and CEO of PRB Pharmaceuticals. "In life or death situations, people tend to take matters into their own hands rather than relying on government institutions."

(I-Newswire) - "People are very concerned about the lack of adequate government stockpiles of anti-viral medications. This is especially true in developing countries, many of which are afflicted with bird flu. Unfortunately, wealthy Western nations were allowed to purchase most of the world's supply of prescription anti-viral medications," added Dr. Hensley. "Starting with this production cycle, we are earmarking 50% of our inventory for people in d eveloping nations. From a humanitarian and world health perspective, keeping these nations supplied with medication is the correct thing to do."
PRB Pharmaceuticals has a strong presence in Southeast Asia and the company has recently started working with Vietnam government officials to help bring the bird flu crisis under control.
VIRA 38 first gained notoriety during the Taiwan SARS outbreak of 2003 when it was used by the Taiwan Presidential staff and doctors at Sungshan Hospital ( SARS management facility ) and again in the spring of 2004 when it was discovered that compounds in VIRA 38 block bird flu virus
( H5N1 ) infections. About VIRA 38
VIRA 38, PRB Pharmaceuticals' over-the-counter broad spectrum anti-viral medication, is known for its effectiveness in treating and preventing influenza. VIRA 38 has recently been shown to contain compounds that inhibit the bird flu ( H5N1 ) virus. Researchers at the Chinese University of Hong Kong have previously discovered these same compounds to be effective against a variety of pathogens, including SARS CoV, the virus responsible for causing severe acute respiratory syndrome.
About PRB Pharmaceuticals
PRB Pharmaceuticals, Inc.
( prbpharmaceuticals.com ) is based in Irvine, California, and Hong Kong. PRB Pharmaceuticals is a fully integrated biopharmaceutical company that develops unique and highly efficacious anti-viral treatments and preventative therapies.
About Lee's Pharmaceuticals
Lee's Pharmaceutical Holdings Ltd
( www.leespharm.com/EN ) ( Hong Kong Exchange GEM
Stock:8221 ) distributes VIRA 38 to the Hong Kong market. Lee's is an integrated research-driven and market-oriented pharmaceutical company engaged in the development, manufacture and sales of quality biopharmaceutical products that focus on combating cardiovascular and viral diseases.
Web sites:
http://www.prbpharmaceuticals.com
http://www.leespharm.com/EN
For further information:
Vivian Fung
+852-2314-1282, +852-2314-1708 ( Fax )
Charles B. Hensley, Ph.D.
Chairman & Chief Executive Officer
PRB Pharmaceuticals
chensley@prbpharmaceuticals.com

If you have questions regarding information in this press release contact the company listed below. I-Newswire.com is a press release service and not the author of this press release. The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies / PR Agencies submit their press releases once per week/month or quarter, make sure check the official company website for accurate release dates as our site displays the I-Newswire.com distribution date only. We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.

Published on:
2005-07-18

Floyd

June 25, 2009 6:00 PM

Inventor of Zicam R Steven DAVIDSON got his Excelsior College degree in 2004 way after he got his diploma mill degree. Before this he used his Ph.D/MBA from the DIPLOMA mill "The American University of Asturias" (SPAIN). Davidson claimed to have a Ph.D and MBA from the diploma mill and when he invented Zicam in the late 90's was out promoting Zicam calling himself a Doctor.

Davidson received his diploma mill Ph.d and MBA without having an undergraduate degree. (A great accomplishment)

It was a great SCAM and fraud on the public.

In one artical he claimed to have a degree from Columbia. (SEE BELOW(
Which he did not

Here is Zicams inventor talking about days at the DIPLOMA MILL

----------------------------------------

Davidson’s knack for business goes back to his days at American University in Asturias, Spain where he examined the European way of doing business. “I wanted to understand how people in the rest of the world did business and how those cultures worked,” he said. “It was very informal and it made me realize I wanted to start my own business instead of working for somebody else.”

Growing up in a small family in New York, DAVIDSON felt he always had a knack for learning and science. With a police officer for a father and a mother involved in various businesses, DAVIDSON quickly learned the value of hard work and perseverance. “I knew that you always had to try harder to get where you wanted to go,” he said.

Business over medicine
Although he had originally set his eyes on a medical degree, DAVIDSON was fascinated by the intricacies and challenges of business and eventually earned a master’s degree in business administration and a doctorate in biopharmaceutical studies.

“I really loved medicine, but I thought business was the best direction for me,” he said.
Soon DAVIDSON established biotech startup Biotem Cytotechnologies and later formed Gel Tech LLC which eventually became Zengen where he developed Zicam.

The following article was also published in the Orange County Register around the same time period.

San Fernando Valley Business Journal, June 23, 2003 v8 i13 p16(1)
His business acumen helps company in biotech world. (Best Companies in the Valley–A Special Report). (biotechnology company Zengen Inc.)(president R. Steven DAVIDSON)(Company Profile) Carlos Martinez.
Full Text: COPYRIGHT 2003 CBJ, L.P.

*****Article Begins*****

His business acumen helps company in biotech world.

R. Steven “Rob” DAVIDSON always felt he was a problem solver. As president and CEO of Woodland Hills-based Zengen Inc., the 37-year-old DAVIDSON heads what is arguably one of the best financed startup biotechs in the Valley.

DAVIDSON, who is the business brains behind the company, is the architect of the firm’s plan that relies on developing over the counter drugs to help fund ongoing research into the company’s proprietary peptide technology.

Peptides are compounds derived from two or more amino acids combined. Amino acids are the chief components of proteins which are synthesized by living cells.

It was just two years ago that Zengen sold off its interest in Zicam, an over-the-counter cold remedy and nose spray it developed, for $17 million which went toward ongoing research into peptides.
“It’s a strategy that’s managed to work well for us,” said DAVIDSON, who helped engineer the deal.
DAVIDSON figured that since over-the-counter medicines have fewer regulatory issues than prescription-based pharmaceuticals, they could be developed and marketed quickly, giving the company needed revenue to fund research.

Today, DAVIDSON hopes to strike gold again with over-the-counter eyedrops that the company is developing to further fund research efforts.

Such funding strategy is unusual in an industry where research dollars are at a premium, said Brent Reinke, an attorney with Crosby Heafey Roach & May, who helps put together funding deals for biotechs.
“It’s not unheard of, but it’s a creative way of getting funding,” Reinke said.

Davidson’s knack for business goes back to his days at American University in Asturias, Spain where he examined the European way of doing business. “I wanted to understand how people in the rest of the world did business and how those cultures worked,” he said. “It was very informal and it made me realize I wanted to start my own business instead of working for somebody else.”

Growing up in a small family in New York, DAVIDSON felt he always had a knack for learning and science. With a police officer for a father and a mother involved in various businesses, DAVIDSON quickly learned the value of hard work and perseverance. “I knew that you always had to try harder to get where you wanted to go,” he said.

Business over medicine
Although he had originally set his eyes on a medical degree, DAVIDSON was fascinated by the intricacies and challenges of business and eventually earned a master’s degree in business administration and a doctorate in biopharmaceutical studies.

“I really loved medicine, but I thought business was the best direction for me,” he said.
Soon DAVIDSON established biotech startup Biotem Cytotechnologies and later formed Gel Tech LLC which eventually became Zengen where he developed Zicam.

By joining with Dr. James Lipton, the creator of the peptide technology, DAVIDSON sought to show the biotech and investment communities that the peptide molecules would work in different anti-bacterial and anti-microbial technologies.

“We could do all kinds of great things, but we couldn’t afford to go for the big one,” DAVIDSON said.
“We went for a soft target — so we went for the anti-microbial or a treatment for yeast infections.”
So far; the peptide molecules are showing promise in treating yeast and other infections, including serving as a therapy for organ rejection.

Davidson’s business strategy and appreciation for the technology isn’t lost on Lipton, who has been researching peptide molecules since 1966.

“He really has a remarkable business sense and dedication to the work,” Lipton said.
Today, the company has established its subsidiary, Zensano, which develops over-the-counter medicines, to help fund research and. development for biotech products.

With one unit developing over-the-counter products, a second developing products using peptide molecules, and a third unit developing drug delivery systems, DAVIDSON has created a self-sustaining biotech that is arguably the envy of other startups.

As for his future, DAVIDSON hopes to push forward with Zengen’s cutting edge technology.
“Big companies never attracted me,” he said.
“Here, we’re doing a lot of different things so we’re not just a one trick pony. That’s exciting.”

*****Article Ends*****

Partial list of R. Steven Davidson’s Published Education Credentials (Listing 3 different Ph.Ds)

All 5 excerpts are currently available on the web for reference. No need to read entire article. The key sentence is in bold print in order to make it easier to spot.

1. Eat Carbs to Lose Fat
Men’s Fitness Magazine April, 2001
Written by: Steve Stiefel Photos by: David Roth/Stone

http://web.archive.org/web/20030811052300/http://www.mensfitness.com/nutrition/24

Excerpt:
“If you do the same workout every day, you’re going to plateau. It’s the same with your diet,” says R. Steven DAVIDSON, who holds a Ph.D. in biochemistry from Columbia University.

(To my knowledge, no one has called Columbia University and checked whether DAVIDSON received a DIPLOMA. It would sure be interesting to confirm that he never studied there.)

==================================================

TAKEN FROM MEN’S FITNESS MAGAZINE
2. “For helping the body overcome allergies, the only treatment I’m impressed with at all is allergy shots,” says R. Steven DAVIDSON, who has a doctorate in natural health sciences. “When you receive an allergy shot, you’re generally given a small dose of the allergen itself, which helps your body develop an immune response to that substance. Allergy shots help to desensitize the body’s response to allergens, and this may be the only treatment’ that truly works.”

(To view entire article, please paste the entire link into your web browser)
http://www.findarticles.com/cf_0/m1608/8_18/89389718/p3/article.jhtml?term=
===============================================

TAKEN FROM MEN’S FITNESS MAGAZINE
3. “Save your high-carb meals for your off days,”confirms R. Steven DAVIDSON, who holds a doctorate in biochemistry. “You’re loading up on long-term energy you’re going to use later on, not right away.” But remember that the point of the high-carb rotation system is to increase metabolic efficiency, not to allow you to binge on your favorite sweets once or twice a week.

(To view entire article, please paste the entire link into your web browser)
http://www.findarticles.com/cf_0/m1608/10_17/80309844/p2/article.jhtml?term=
=================================================
TAKEN FROM ZENGEN’S WEBSITE

4. Dr. DAVIDSON received his MBA in International Finance and Ph.D. in Biopharmaceutical Project Management from the American University of Asturias, Spain and performed post graduate studies at Villanova University.
DAVIDSON.htm' target='_blank'>http://web.archive.org/web/20030624041237/http://www.zengen.com/board_of_directors_DAVIDSON.htm

The above page was recently removed from the Zengen website. http://www.zengen.com but can still be found at the web archive.

The exact same exact bio was recently removed from patentdiscovery.com and from innozen.com, which are other businesses he is/was involved in.

(A Ph.D. in Biopharmaceutical Project Management is at best, highly unusual)

The American University of Asturias
(The American University of Asturias was a DIPLOMA mill which was shut down by the Spanish government. It was denominated and shut down about 4 or 5 years ago for issuing illegal diplomas in Spain.) The Spanish government invalidated their diplomas. This can be verified by visiting several Spanish websites translated to English. These web pages still exist on the Internet.

Until very recently, DAVIDSON openly publicized his American University of Astrurias Ph.D. DIPLOMA on his websites. Matrixx Initiatives still refers to R. Steven DAVIDSON contributions to the development of Zicam using the Ph.D. and MBA designations after his name.

==================================================
TAKEN FROM MEN’S FITNESS MAGAZINE
5. “The most important way to affect your total cholesterol is through improving diet and incorporating appropriate exercise,” says R. Steven DAVIDSON, who has a doctorate in biochemistry. Even if you’re eating reasonably clean, you might be surprised at the effects a little more attention to diet can have on total cholesterol.

(To view entire article, please paste the entire link into your web browser)
http://www.findarticles.com/cf_0/m1608/9_17/80309796/p3/article.jhtml?term=

OTHER CURRENT EXAMPLE OF DAVIDSON’S PUBLIC EFFORTS TO PUBLISH HIS FALSE EDUCATIONAL CREDENTIALS:

http://chi.org/home/directory.php?pid=1&cid=2820&mode=2&mom=0

The Men Behind Zicam

Tuesday, January 31, 2006
Page HE05
http://www.washingtonpost.com/wp-dyn/content/article/2006/01/30/AR2006013001255.html

Like other scientific entrepreneurs, Robert Steven DAVIDSON thought zinc might be a promising treatment for the common cold. But unlike many inventors of drugs, DAVIDSON and his colleague Charles B. Hensley, who hold patents on Zicam, have unusual backgrounds.

DAVIDSON received a bachelor's degree in 2004 from a "virtual" university, Excelsior College in Albany, N.Y. He lists himself as a PhD, a degree he obtained from an unaccredited and now-defunct university in Spain.

His colleague and co-inventor Hensley holds a doctorate in physiology from the University of Southern California and is currently chief executive officer of PRB Pharmaceuticals based in Cypress, Calif. Hensley recently received a warning letter from the Food and Drug Administration (FDA) about the sale over the Internet of an unapproved drug his company makes to treat bird flu. Hensley previously developed a weight-loss remedy that involves sniffing "specially developed aromas."

DAVIDSON, who has contributed articles to Men's Fitness magazine, says his doctorate in biopharmaceutical project management and his MBA in international finance were earned at the American University of Asturias in Asturias, Spain, in the late 1990s. The school was closed in 2000 for violations of Spanish law, records show, and is considered a DIPLOMA mill by American authorities.

DAVIDSON, who sold his interest in Zicam several years ago when he left to start another biotech firm, said he was unaware of any problems with the school in Spain. It is unusual to earn a doctorate before a bachelor's degree, he said in an interview, but his advanced degrees are legitimate. "I did work, a research paper and a dissertation."

He declined to discuss whether any safety questions arose during Zicam's development and testing.

DAVIDSON said he met Hensley years ago at Cleveland Chiropractic College in Los Angeles, where he was taking classes and Hensley was a professor.

On Nov. 23, the FDA sent Hensley a letter about Vira 38, an antiviral compound marketed on PRB's Web site as effective in treating influenza, bird flu and SARS. The regulatory agency told Hensley he was violating federal law by selling an unapproved drug and warned that he and his company could face further legal action including "seizure of illegal products."

Hensley did not respond to e-mails or telephone calls.

-- Sandra G. Boodman

http://www.washingtonpost.com/wp-dyn/content/article/2006/01/30/AR2006013001255.html

Cynthia

June 25, 2009 9:44 PM

I just found this interesting site about health problems and the loss of taste and smell from which some Zicam users have suffered. There is also important safety information here:
http://www.zicam-smell-loss-lawyer.com/

spanish lover

June 26, 2009 7:43 AM

Your blog is very helpful. Links are great and interesting.
spanishlover

Tani Sunarjo

June 27, 2009 3:51 PM


I have ben for more than 45 years in the pharma business including representing 26 multinational companies including 5 USA companies ( Ayerst,W.H.Rorer,Block Pharma,etc), Pasteur-Merieu,Leo Pharma etc' but I had made the medical seeding trials with 200 bottles of Vira 38 and have to admit that I have never experienced such a natural product which can clear the clinical indication in influenza patients in such a short time , 3-4 days ; not a weekor more like the modern chemical influenza formulated products. In 1976 I already read the papers about the study of the Fish Oil ( now known as Omega-3) among the Eskimos people, but funny why the American healthcare industries only start to acknowledge the benefit of Omega-3 in 2003. Lots of natural medicines have medical efficacy but the FDA says NO. Ofcourse such formulation could not be Patented for 20[ years. Do the American people knew that after the Civil War doctors only use the herbal Valerian as tranguilizer for tghe more than 600.000 wounded soldiers (Union + Federal). It is funny. Tamiflu is half a herbal product, why approved for Malaria ? It is like 1 man is only blind on one eye and because the rest are all blind, so the one eye blin mand becomes the president.

I am not an agent of the Vira 38 manufactuerer, but only interested in their natural formula. Yes it prevents the intercellular-uncoating of the Virus Cell and prevent it entering the healthy CD4 cell.

Tani Sunarjo

June 27, 2009 3:55 PM


I am living in Indonesia

Dawn

June 28, 2009 10:38 PM

My family, including my children have used the Zicam nasal products for several years and SWEAR by its effectiveness and safety. As a loyal customer who virtually relied on this brand to help prevent colds, especially in my young asthmatic son, I feel utterly lost not having this product available for my use.

I pray the Matrixx company is successful in defending itself against these claims and are able to prove the safety of its Zicam brand. I can't help but feel the insurance and health care industry (especially the pharma companies) aren't somehow involved in shutting out this great product from the public, as it must be a real source of money-loss for those who cash in on the common cold year after year.

Good luck Matrixx, I want my Zicam back!

Cynthia

June 29, 2009 9:34 PM

I just found this interesting site about health problems and the loss of taste and smell from which some Zicam users have suffered. There is also important safety information here:
http://www.zicam-smell-loss-lawyer.com/

Brad

July 5, 2009 11:42 AM

This swab product worked well,considering all the causes of anosmia.Why is the FDA picking 130 cases as the problem for ZICAM.Maybe the 130 cases stuck the swab into their collective brains but used properly,it help a lot. Shorting a cold or stopping it. Which,much like the product stevia.The FDA called poison and forced the product Nutrisweet,Aspartane on us and didn't Stevia a natural plant turn out to be the better product?? Cost Stevia a fortune,made Redpath a fortune as most of the Sugar Cartel products are all preverted Sugar Cane!
Keep up the fight ZICAM ,THanks

Joshua

August 13, 2009 3:14 AM

Here is more information on Matrixx losses suffered since Zicam was linked to the loss of a sense of smell: http://www.newsinferno.com/archives/11706#more-11706

Joshua

September 16, 2009 11:45 AM

Matrixx said it won't reformulate the Zicam products it had to recall: http://www.newsinferno.com/archives/12276#more-12276

Claudia

November 11, 2009 6:18 AM

Thank you for a wonderful post. Useful information and good follow up comments.

rocket spanish

chiropractic internet marketing

March 13, 2010 10:56 PM

Right the point. Thanks for your nice information. As well as other marketing system chiroparctic marketing system should be well defined, targeted and verified. The good news is online marketing tools are very easy to reach and have advantage.

chiropractic internet marketing

chiropractic internet marketing

March 13, 2010 10:59 PM

Right the point. Thanks for your nice information. As well as other marketing system chiroparctic marketing system should be well defined, targeted and verified. The good news is online marketing tools are very easy to reach and have advantage.

chiropractic internet marketing

Post a comment

 

About

How can you manage smarter? Bloomberg Businessweek contributors synthesize insights from the brightest business thinkers, critique the latest management trends, and comment on leaders in the news.

BW Mall - Sponsored Links

Buy a link now!